Todos Medical Ltd. · OTC:TOMDF
Todos Medical — Investor Presentation (October 2016)
19 slides from Todos Medical's investor presentation, October 2016
Slide 1: Next Generation Cancer Screening
NEXT GENERATION CANCER SCREENING MEDICAL October 2016
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements, including, without limitation, statements containing the words “believes”, “expects”, “plans”, ”estimates” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors wh
Slide 3: Our Vision
OUR VISION Blood test as first line method and standard of care for cancer screening 3 MEDICAL
Slide 4: Investment Highlights
Investment Highlights Accessible, Innovative Blood Test Technology Platform for Cancer Screening Innovative, blood test based method for cancer screening Non-invasive, rapid, and lower cost Large, addressable global market Relative accessibility of a blood test for cancer screening Next generation p
Slide 5: Experienced Leadership
Experienced Leadership Proven Record for Results Delivery Todos Medical Ltd. • Over 25 years of R&D, Marketing, Sales and Management experience • Seasoned executive at technology companies Rami Zigdon MBA, EENG, BSc • Country Manager, Hitachi Semiconductors, Renesas Technology, & Atmel CEO, Co-found
Slide 6: Robust Cancer Screening from a Simple Blood Test
Driving Innovation at the Lab without Change to Current Physician Practices Robust Cancer Screening from a Simple Blood Test Fast Automated results Simple (blood test) Robust platform with ability to Low cost screen for additional cancer types Radiation free Scalable 6 MEDICAL
Slide 7: How it Works
How it Works Results from Standard Blood Test Delivered in 3 Hours Standard Blood Mononuclear Cells & FTIR1 Analysis with Results Draw with Todos Kit Plasma Separated Todos Algorithm Reported to Doctor Note: Fourier Transform Infra-Red (FTIR) spectroscopic analysis of the immune system‘s response to
Slide 8: Overall Market Opportunity
Overall Market Opportunity Total available market (TAM) estimated at more than 600M tests a year in 2021 Breast and colorectal cancer screening are initial applications Additional indications planned to follow, with increasing penetration and adoption Note: Based on Todos Medical calculations 8 MEDI
Slide 9: First Line Program in Breast Cancer Screening
First Line Program in Breast Cancer Screening Centralized Evaluation with Primary Physician for More Cost-Effective Work up Mammography shortfalls in dense breast tissues • Tissue density challenges breast cancer screening • 50% of women are poorly diagnosed (low sensitivity in BI-RADS 3 & 4) • High
Slide 10: Large Breast Cancer Screening Market
Large Breast Cancer Screening Market $2.2B Market for Breast Cancer Screening U.S. E.U. 50 M1 Eligible for Screening 64 M2 $1B Potential Market $1.2B 1. American Cancer Society, 2009 Early 2. Source: European Commission: Prevention & Early Detection Facts and 2008 Report, Cancer Screening in Figures
Slide 11: First Line Approach in Colorectal Cancer Screening
First Line Approach in Colorectal Cancer Screening Novel Blood Test Feature Sets for Increased Compliance and Prevention Colonoscopy – An effective prevention measure, but patient compliance is low • Colonoscopy requires fasting and an invasive procedure • More than 60% of patients refuse colonoscop
Slide 12: Large Colorectal Cancer Screening Market
Large Colorectal Cancer Screening Market $4.3B Market for Colorectal Cancer Screening U.S. E.U. 94 M1 Eligible for Screening 107 M2 $2B Potential Market $2.3B 1. American Cancer Society, 2009 Early 2. Source: European Commission: Prevention & Early Detection Facts and 2008 Report, Cancer Screening i
Slide 13: Todos Medical Platform Solution: FTIR Analysis of Plasma and PBMCs
Todos Medical Platform Solution FTIR Analysis of Chemical Composition of Plasma and PBMCs Immune response to tumors and cancer cells APCs, T cells, and B cells actively respond to cancer, resulting in biochemical changes FTIR advancements facilitate distinction in biochemical compositions Fourier Tr
Slide 14: Immune Response Acts as Body's Sensor for Cancer
Todos Medical Platform Solution Immune Response Acts as Body’s Sensor for Cancer Analysis of total biochemical changes of Plasma and PBMCs Quantity and conformation of the macro-molecules characterized Biochemically distinct differences in cancer vs. healthy controls Breast, colon, and other cancer
Slide 15: Clinical Results Show High Sensitivity & Specificity
Todos Medical Platform Solution Clinical Results Show High Sensitivity & Specificity Breast Cancer Screening Light absorption Light frequency -5 2.0x10 Colon Cancer Screening -5 1.0x10 Light absorption 0.0 -5 -1.0x10 -5 -2.0x10 Healthy Benign -5 -3.0x10 CRC 1100 1080 1060 1040 Light frequency 1020 1
Slide 16: Publications on Clinical Results
Publications on Clinical Results Clinical Support for Feasibility in Breast and Colorectal Cancer Screening Four Peer Reviewed Publications Over 80% sensitivity and over 80% specificity achieved in most recent studies • June 2015, Colorectal Cancer Screening: Barlev et al. Journal of Gastroenterolog
Slide 17: Global Regulatory Plan
Global Regulatory Plan Multi-Pronged Development Plan Europe(+ Israel) Singapore + Asia Plans for the US CE Mark approved for Breast cancer clinical trials Planning and Pre-IDE European sales in Singapore; colon cancer meetings with the FDA For commercialization to follow IDE filing and initiation o
Slide 18: Investment Conclusion
Investment Conclusion Accessible, Innovative Blood Test Technology Platform for Cancer Screening Innovative, blood test based method for cancer screening Non-invasive, rapid, and lower cost Large, addressable global market Relative accessibility of a blood test for cancer screening Next generation p
Slide 19: Thank You! For Additional Information
Thank You! For Additional Information: NEXT GENERATION CANCER SCREENING MEDICAL Rami Zigdon CEO Telephone: +972-54-638-0666 | Fax: +972-8-633-3964 [email protected] 19